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Imaginary Worlds: The Status of Modeled Quality Adjusted Life Year Claims for New Oral 
Anticoagulants in Atrial Fibrillation Published Between January 2012 and February 2016 
Paul C. Langley, PhD ; Taeho Greg Rhee, PhD(c)  
College of Pharmacy University of Minnesota 
 
Abstract 
The purpose of this commentary is to evaluate modeled quality adjusted life year claims (QALYs) for new oral anticoagulants (NOACs) 
published in the period from January 2012 to February 2016. The focus of this commentary is to assess whether or not the modeled 
claims meet the standards of normal science in supporting falsification and replication. A systematic and consensus review by the 
authors identified a total of 23 cost-utility NOACs evaluations along with four single technology appraisals undertaken by the 
National Institute for Health and Care Excellence (NICE) in the UK. Each study was evaluated in terms of four criteria: (i) did the study 
generate evaluable claims (ii) id the authors attempt to generate evaluable claims (iii) did the authors suggest how the claims might 
be evaluated and (iv) did the authors caution readers as to the implications of generating non-evaluable projections or claims for 
credibility in health system decision making? None of the 23 studies assessed or the four NICE single technology appraisals met any of 
the four assessment criteria. None of the studies presented projections or claims in a form suitable for empirical evaluation. None 
could support falsification or replication. They failed the standards associated with the scientific method. Failure to meet the 
standards of normal science meant that the studies, from a formulary assessment perspective, are not credible. The claims made 
were either impossible to verify, or if potentially verifiable, were not presented in a testable form. There was no basis for assessing 
whether the claims were right or even if they were wrong. This lack of scientific credibility is a major concern. In particular, the choice 
of a lifetime cost-utility framework for assessing the NOACs against warfarin and against each other effectively precludes any 
experimental assessment. If medical economics is to advance through the formulation and testing of hypotheses, then editors of 
journals should consider whether or not to set standards for the acceptance of publications to include the requirement for testable 
claims and the results of claims assessment. If this is not acceptable, then it should be made clear that published modeled claims and 
simulations are simply imaginary worlds or thought experiments. Editors cannot sit back and assume that at some time in the future 
non-testable projections will possibly be evaluated.   
 
 
Keywords: new oral anticoagulant (NOAC), quality-adjusted life years (QALYs), modeling, credibility, imaginary worlds, 
pseudoscience, adherence 
 
 
 
Introduction  
The entry of new oral anticoagulants (NOACs) into treatment 
practice for non-valvular atrial fibrillation has led to a 
substantial investment in a number of modeled and 
simulated claims for product cost-effectiveness. These 
technology assessments have included comprehensive 
simulated comparisons between warfarin and all competing 
NOACs, as well as individual NOAC comparisons against 
warfarin and each other. A common feature of these models 
or simulations has been their attempt to extrapolate from 
pivotal phase 3 randomized controlled trials (RCTs) to capture 
constructed clinical events and direct medical costs 
attributable to the comparator OACs over the lifetime of the  
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patient cohort. The respective pivotal trials are: edoxaban 
ENGAGE-AF; dabigatran RE-LY; rivaroxaban ROCKET-AF; and 
apixaban ARISTOTLE 1 2 3 4 .  The common element has been 
to demonstrate that the entry of the NOACs into clinical 
practice and the switching from warfarin in non-valvular atrial 
fibrillation can be justified, not only on clinical grounds, but in 
terms of projected cost-utility outcomes and willingness-to-
pay from a health system perspective. Needless to say, from 
manufacturing and marketing perspectives this is a highly 
competitive market. 
 
The purpose of this commentary is to consider how credible 
the claims for NOACs are in non-valvular atrial fibrillation. The 
review covers the period from January 2012 to February 
2016. Credibility in this research program is determined by 
the standards of normal science: Does the projection or claim 
for a product support falsification and replication? 5  6 If, in 
applying the recognized standards that support the scientific 
method, the judgment is that the claim lacks credibility, then 
the recommendation is that the claim should be rejected 7 8.  
In focusing on the claims, irrespective of the perceived merits 
of the model or simulation generating those claims, if they 
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fail the standards of falsification and replication, then they 
are not credible inputs for health care decision making 9 10 11. 
The standards of normal science are absolute. A constructed 
model or simulation does not test hypotheses. 
 
This commentary is part of an ongoing evaluation of 
formulary evidentiary standards supported by the Social and 
Administrative Pharmacy Program at the University of 
Minnesota College of Pharmacy. A number of commentaries 
have already been published. These have focused on (i) the 
proposed Minnesota guidelines for formulary evaluations 12; 
(ii) standards for health technology assessments published in 
three leading journals: Pharmacoeconomics, Value in Health 
and the Journal of Medical Economics 13 14 15 ; (iii) guidelines 
for formulary submissions by the Academy of Managed Care 
Pharmacy (AMCP)  in the US and by the National Institute for 
Health and Care Excellence (NICE) in the UK and the 
Pharmaceutical Management Agency (PHARMAC) in New 
Zealand 16 17 18 ; and (iv) the inappropriateness of quality 
adjusted years (QALY) as a recommended ‘gold standard’ 
outcome measure in value claims for competing 
pharmaceuticals 19 20 . 
  
Methods 
A systematic review, using the PRISMA-P checklist, of 
PubMed with MeSH terms ‘atrial fibrillation AND cost AND 
effectiveness AND utility’ (as of March 24, 2016) yielded 52 
studies 21. Supplementary searches of the bibliography of 
each study were also undertaken and abstracts extracted. All 
abstracts were then reviewed independently by both authors 
with an agreed final selection based on three criteria. These 
criteria were:  
• Did the study compare one or more NOACs against 
the standard of care warfarin? 
• Did the study utilize a decision model or simulation? 
• Did the study present claims for competing 
therapies?  
A total of 23 studies were identified. These were classified as: 
• Comparative cost-effectiveness reviews: all NOACs: 9 
studies 
• Comparative cost-effectiveness  reviews: single 
NOAC: 1 study 
• Comparative cost effectiveness: dabigatran vs. 
warfarin: 3 studies 
• Comparative cost effectiveness: rivaroxaban vs. 
warfarin: 4 studies 
• Comparative cost effectiveness: apixaban vs. 
warfarin/other NOACs: 4 studies 
• Comparative cost effectiveness: edoxaban vs. 
warfarin: 2 studies 
 
  
To evaluate the credibility of a study, each author reviewed 
the study in terms of four criteria. These are: 
• Did the study generate evaluable claims? 
• Did the author(s) attempt to generate evaluable 
claims? 
• Did the authors suggest how the claims might be 
evaluated? 
• Did the author(s) caution readers as to the 
implications of generating non-evaluable claims for 
the credibility of the analysis in health system 
decision making? 
 
There was no restriction on the type of claim. A claim could 
be expressed in cost-effectiveness terms, it could be 
expressed as quality adjusted life years (QALYs) gained, it 
could be expressed as direct medical costs or it could be 
expressed as adverse clinical events avoided. Irrespective of 
the claim made, this was assessed in the context of providing 
feedback to a formulary committee to support ongoing 
disease area and therapeutic reviews.  
 
If these credibility standards are accepted, then the 
responsibility is on the authors of a modeled claim or 
simulation to structure their analysis to generate evaluable 
claims. If claims are put in cost-utility terms, then it has to be 
shown how those claims might be evaluated. If claims are 
expressed in adverse events avoided or if the claims were 
disaggregated by a base-line risk of stroke, again it should be 
shown how those claims are to be assessed. If the claims rest 
on assumptions of product discontinuation or 
adherence/persistence behavior, then once again it should be 
indicated how these data are to be captured.   
 
As well as reviewing the selected papers, the analysis also 
considered four single technology assessments by NICE for 
dabigatran, rivaroxaban, apixaban and edoxaban 22 23 24 25. 
These were chosen because they all subscribe to a common 
model format, the NICE reference case 26. The reference case 
is important in health technology assessment because it has 
been adopted as the preferred format for formulary 
submissions in a number of single payer health systems 27 28. 
It has also influenced the Academy of Managed Care 
Pharmacy (AMCP) Format for Formulary Submissions in the 
US 29 . Through standards established by professional groups 
such as the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) and the adoption of quality 
check lists such as CHEERS, the reference case standard has 
had a significant effect on the widespread adoption of 
constructed, lifetime cost-per-QALY models to generate non-
evaluable claims for product performance 30 31 32. In none of 
these guidelines is there any requirement for projections or 
claims for cost-effectiveness to be put in evaluable terms.  
 
 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                           2016, Vol. 7, No. 3, Article 7                          INNOVATIONS in pharmacy   3 
 
Results 
The results are presented in Table 1 under four heads: 
• Study and country 
• Sponsor (if stated) 
• Type of modeled or simulated claim 
• QALYs gained by OAC 
 
As all studies evaluated utilized a lifetime cost-per-QALY 
framework, QALYs gained were chosen as the representative 
outcome claim. This avoided attempting to rationalize 
country specific estimates of direct medical cost and resultant 
incremental cost-effectiveness ratios (ICERs). QALYs are also 
of interest because while QALY gains for the OAC 
interventions are potentially substantial in years of life 
gained, the results of the pivotal phase 3 RCTs would suggest 
that QALY gains between the individual OACs are less 
substantial.  Even so, costs and QALYs are not independent of 
each other; they are both constructed from the underlying 
clinical event structure. 
  
The results of the systematic review are presented in Table1. 
The key findings are as follows: 
• All studies presented claims in lifetime cost-utility 
terms (the term lifetime could vary from a minimum 
time horizon of 20 years to death); 
• All of the studies extrapolated from the pivotal 
phase 3 trials for the respective NOACs utilizing a 
Markov framework; 
• None of the studies presented claims in evaluable 
terms; 
• None of the authors attempted to generate or 
suggest possible evaluable claims; 
• None of the authors suggest how the claims might 
be evaluated; and 
• None of the authors cautioned the reader as to the 
constructed nature of non-evaluable claims.  
 
 
Constructed QALYs Gained   
In virtually all models or simulations projected QALY gains are 
similar. Comparisons between the various OACs point to the 
comparative gains being measured in days or months rather 
than years. While these should not be taken at face value it is 
important to put them in the perspective of the survival rates 
of the constructed atrial fibrillation cohorts. For example, the 
Coyle et al study, which covered all OACs, yielded estimates 
of QALYs gained, for a lifetime cohort with average age of 72 
years, ranging from 6.480 years to  6.543 years (or a range of 
23 days; 0.063 of 365 days) 35. The Harrington et al study 
which compared warfarin, rivaroxaban, dabigatran (150mg) 
and apixaban yielded, for a hypothetical cohort of 70-year-old 
patients, QALYs gained ranging from 7.97 for warfarin to 8.47 
for apixaban (or a range of 6 months) 40. Within the NOACs 
the incremental gain was only 0.21 QALYS (2.5 months). The 
Krejczy et al. modeling for Germany yielded for a follow-up 
period of 20 years extrapolated from the principal RCTs a gain 
of 0.04 QALYS comparing dabigatran 110mg with warfarin (15 
days), 0.07 QALYS comparing dabigatran 150 mg with 
warfarin (26 days), 0.08 QALYs comparing rivaroxaban with 
warfarin (29 days) and 0.21 QALYs for apixaban comparing 
apixaban with warfarin (77 days) 38. The Lantis et al study29, 
which again utilized a lifetime Markov 6-week cycle model 
(adapted from models developed by Dorian et al and Lip et al. 
55 57) generated discounted QALY estimates of 6.099 for 
warfarin, 6,289 for apixaban, a range of 6.186 to 6.221 for 
dabigatran and 6.242 for rivaroxaban 39. Although the study 
claimed that apixaban dominated the other NOACs, the gain 
in terms of QALYs is relatively small. In respect of warfarin, 
the gain was 69 days and for rivaroxaban 17 days.   
 
The Harrington et al assessment of competing NOACs and 
warfarin found for a cohort of 70-year old patients a 
difference between dabigatran and apixaban of 0.06 QALYs 
and a superiority of dabigatran over rivaroxaban of 0.15 
QALYs 40. Similar comparisons for models in Portugal for a 73-
year old cohort yielded an increment of 0.02 QALYs 
comparing rivaroxaban to warfarin, while a similar 
comparison for Belgium yielded an increment of 0.11 QALYs 
50 52 .  
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Table 1 
Imaginary Worlds: Status of Comparative Incremental QALY Claims for NOACs January 2012 to March 2016 
Study [country] Sponsor  
 (if any) 
Modeled or Simulated Claims QALYs Gained (base case) 
Comparative cost-effectiveness reviews: all NOACs 
Jarungsuccess and Taerakun 
[Thailand]33 
None stated Markov 30-year time horizon 1-year cycle  Warfarin: 2.29 
Dabigatran 110mg: 2.29 
Dabigatran 150mg: 2.34 
Apixaban: 2.33 
Rivaroxaban: 2.31 
Coyle et al [Canada]34 Canadian 
Institutes of 
Health 
Research 
Markov 20-year, 10-year and 2-year time horizon.  Warfarin: 6.480 
Dabigatran 110mg: 6.543 
Dabigatran 150mg: 6.617 
Apixaban: 6.617 
Rivaroxaban: 6.541 
Edoxaban: 6.543 
Vestegaard & Ehlers 
[Denmark]35 
None stated Markov 10-year time horizon3-month cycle 
length with starting age of 70 years (with 
extension to lifetime) 
Model to assess cost-effectiveness of 
implementing a national treatment 
strategy of strict adherence to 2012 ESC 
guidelines compared to previous strategy. 
Base-case estimated QALY gain of 5.316 
compared to 4.942.  
Wu et al [China]36 Program of 
Shanghai 
Chief Science 
Markov state transition lifetime cost-per-QALY 
model comparing rivaroxaban, warfarin, aspirin 
plus clopidogrel, aspirin and no intervention. 
Cycle length 1-month. 
No prevention: 3.33 
Aspirin: 3.6 
Aspirin plus clopidogrel:3.81 
Warfarin: 3.93 
Rivaroxaban: 4.08 
Krejczy et al [Germany]37 None stated Lifetime cost-per-QALY Markov model for a 
hypothetical cohort of patients at 65 years of age 
at increased risk of stroke 
Warfarin: 6.480 
Dabigatran 110mg: 6.543 
Dabigatran 150mg: 6.617 
Apixaban: 6.617 
Rivaroxaban: 6.541 
Edoxaban: 6.543 
Lantis et al [France]38 Pfizer and 
Bristol-Myers 
Squibb 
Markov lifetime 6-week cycle cost-per- QALY 
model comparing apixaban, dabigatran 
,rivaroxaban, warfarin and aspirin: warfarin and 
apixaban optimal treatment choices, with 
apixaban cost-effective alternative to warfarin 
Warfarin: 6.099 
Dabigatran 110mg: 6.186 
Dabigatran 150/110 mg switch: 6.220  
Dabigatran 150mg: 6.221 
Apixaban: 6.289 
Rivaroxaban: 6.242 
Harrington et al [US]39 None stated Lifetime cost-per-QALY Markov model for a 
hypothetical cohort of 70-year old patients at 
increased risk of stroke 
Warfarin: 7.97 
Dabigatran 150mg: 8.41 
Apixaban: 8.47 
Rivaroxaban: 8.26 
Rognoni et al [Italy]40 None stated Decision tree combined with a lifetime cost-per-
QALY Markov model with a 3-month cycle for a 
hypothetical cohort of 71-year olds differentiated 
by CHADS2 score 
CHADS2 ≤ 1 
Warfarin: 11.133 
Apixaban: 11.890 
Dabigatran: 12.223 
CHADS2 = 2 
Warfarin :8.764 
Apixaban: 9.402 
Dabigatran: 9.587 
Rivaroxaban: 9.122 
CHADS2 ≥ 3 
Warfarin: 7.127 
Apixaban:7.997 
Dabigatran: 7.518 
Rivaroxaban: 7.581 
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Kongnakorn et al [Belgium] 41 Pfizer and 
Bristol-Myers 
Squibb  
Lifetime Markov model with 6-week cycle Incremental results vs. warfarin 
Dabigatran 110mg: 0.078 
Dabigatran 110/150mg:0.118 
Rivaroxaban: 0.132 
Apixaban: 0.193 
 
Comparative cost-effectiveness reviews : single NOACs 
Sorensen et al 42 Boehringer 
Ingelheim 
International 
GmbH 
Systematic review of dabigatran lifetime Markov 
cost-utility models to evaluate key model 
features to account for cost and QALY differences 
vs. warfarin 
UK setting: incremental QALY 
Base case Kansal et al: 0.242 
Base case Pink et al: 0.14643 
 
US setting: incremental QALY 
Base case: Sorensen et al44: adapted to 
Freeman et al45/Shah and Gage46: 0.183 
Base case: Freeman et al: 0.56 
Base case: Shah and Gage: 0.25 
 
Comparative cost effectiveness: dabigatran vs. warfarin 
You et al [US]47 None stated Markov cost-utility model with 25 year horizon 
and a monthly cycle. Starting age 65 years 
Genotype guided AC: 9.554 
Usual AC: 9.444 
Dabigatran 150mg:10.065 
Dabigatran 110mg:10.026 
Miguel et al [Portugal]48 Boehringer 
Ingelheim Lda  
Lifetime Markov cost-utility model with 3-month 
cycle 
Dabigatran: 0.439 gain (therapy before 
the age of 80 years) 
Dabigatran: 0.166 gain (therapy begins 80 
years and over) 
Kansal et al [Canada]49 Boehringer 
Ingelheim 
International 
GmbH 
Lifetime Markov model with 3 month cycle and 
simulated age of 71 years (primary analysis – 
dabigatran vs. rivaroxaban; secondary analysis vs. 
warfarin. 
Dabigatran: 6.167 
Rivaroxaban: 6.015 
Warfarin: 5.940 
Comparative cost effectiveness: rivaroxaban vs. warfarin 
Morais et al [Portugal]50 None stated Lifetime (20 year) Markov cost-utility model with 
a cycle length of 3 months. Mean starting age 73 
years 
Warfarin: 3.81 
Rivaroxaban: 3.83 
Mensch et al [Germany]51 None stated Markov cost-utility model over 35 years with a 
hypothetical cohort of 65 year olds with at 
moderate to high risk of stroke with a 30-day 
cycle 
Warfarin: 10.35 
Rivaroxaban: 11.06 
Kleintjens et al [Belgium]52 None stated Markov lifetime cost-utility model with a 
hypothetical cohort  mean age of 73 years  
Warfarin: 10.51 
Rivaroxaban: 10.62 
Kourlaba et al [Greece]53 Bayer Hellas Lifetime Markov model with 3-month cycle with 
starting age of 75 years. 
Warfarin: 6.28 
Rivaroxaban: 6.50 
Comparative cost effectiveness: apixaban vs. warfarin/other NOACs 
Kamae et al [Japan]54 Bristol Myers 
KK and Pfizer 
Japan Inc. 
Lifetime Markov model with 6-week cycle length 
(adapted from Dorian et al) comprising 17 health 
states. Starting age 70 years 
Warfarin: 7.23  
Apixaban: 7.47 
Dorian et al. [UK]55 Pfizer and 
Bristol Myers 
Squibb 
Lifetime Markov cost-utility model with 11 health 
states 
Warfarin: 6.08 
Apixaban: 6.26 
Ademi et al. [Australia]56 Pfizer 
Australia 
State transition Markov model with 1-year cycle 
comparing apixaban and warfarin. The model 
comprised 5 health states and seven transition 
states. Time horizon 20 years (effectively 
lifetime). Starting age 70 years 
 
Warfarin: 5.84  
Apixaban: 6.15  
Lip et al [UK]57 Pfizer and 
Bristol-Myers 
Squibb 
Lifetime Markov model with cycle of 6 weeks and 
11 health states. Starting age 70 years 
Apixaban: 6.26 
Dabigatran 110mg: 6.16 
Dabigatran 150mg: 6.19 
Rivaroxaban: 6.21 
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Comparative cost effectiveness: edoxaban vs. warfarin 
Rognoni et al [Italy]58 None Lifetime Markov model with 3-month cycle Warfarin: 8.425 
Edoxaban: 9.022 
Krejczy et al [Germany]59 None  A 20-year Markov model with a cycle length of 1-
year and a base-case hypothetical population 
with starting age of 65 years who were at 
increased risk for stroke.  
Warfarin :7.48 
Edoxaban 30mg: 7.65  
Edoxaban 60mg 7.69 
 
Warfarin: 7.64 
Dabigatran 110mg 7.68 
Dabigatran 150mg: 7.71 
 
Warfarin 7.59 
Rivaroxaban 20mg: 7.67 
 
Warfarin 7.56 
Apixaban 5mg: 7.75   
 
The NICE Single Technology Appraisals 
In each of the four NICE single technology appraisals, 
manufactures were required to meet the standards of the 
reference case. This mandates a framework consistent with 
the natural course of a chronic disease, which, in practical 
terms, means a lifetime horizon. Model endpoints are to be 
expressed in cost-per-QALY terms. Costs are from the 
perspective of the National Health Service (NHS) and Personal 
Social Services (PPS). QALYs are to be based upon community 
preference utilities with the EQ-5D the preferred instrument. 
Standard techniques are to be applied in the modeling to 
include Markov processes and the application of sensitivity 
and probabilistic sensitivity analysis. Costs and benefits are to 
be discounted at 3.5%. As noted above, there is no 
requirement for the simulated cost-outcomes projections to 
be presented in evaluable terms 
. 
Consistency with the reference case ensures the evidence 
presented to NICE is constructed. As such the projected 
claims are both untestable and immune to failure. The only 
basis for challenging the manufacturer’s modeled or 
simulated claims is through an assessment of the 
‘reasonableness’ or otherwise of the simulation given the 
evidence base for the modeled inputs and assumptions. This 
is achieved through an evidence group (ERG) review of the 
submission, focusing on the quality and scope of the clinical 
inputs and then a review of the structure, assumptions and 
inputs to the cost-utility model. Typically, there is a base-case 
model with supplementary sensitivity and sub-group 
evaluations to assess robustness. The ERG’s review is then 
subject to a further review by the NICE appraisal committee. 
A draft guidance is then prepared, reviewed and a final 
guidance published. 
 
The four manufacturer’s submissions follow a similar model 
structure for all NOACs. In the case of apixaban, the 
manufacturer submitted a Markov cohort model comprising 
18 health states including the absorbing state of death. 
Patients transitioned between health states in cycles of 6 
weeks with only one clinical event permitted per cycle. It was 
noted that, although previous NOAC submissions had utilized 
a similar process, given the influence of individual patient 
characteristics on outcomes in atrial fibrillation, a discreet 
event simulation rather than a Markov cohort modeling 
approach may have been more appropriate. The Markov 
cohort, however, was accepted. The model projected the risk 
of events and treatment discontinuation from the within-trial 
into the post-trial period with the impact of treatment on the 
risk of events assumed to remain constant for the full model 
time horizon. The same approach is taken for the other NOAC 
models.  Utility scores for the various health states, as they 
were not collected in the trials, were estimated from a 
systematic literature review. Unit direct medical costs were 
assumed to be unchanged over the time horizon of the 
model. Together with the constructed utility values they were 
discounted at 3.5%.  
 
The internal validity of the model was evaluated through an 
extreme value analysis to identify any flawed algorithms or 
irregularities. Face validity was assessed by comparison of the 
model assumptions against published results. In this case, the 
projected results were validated against the constructed 
simulated results reported for dabigatran and rivaroxaban. 
The base-case model was presented as a fully incremental 
analysis between all considered interventions. The review 
group assessed the manufacturer’s deterministic results 
against those estimated by the manufacturer’s probabilistic 
sensitivity analysis. A summary of the results is presented in 
Table 2.  
 
The results reported for the deterministic as opposed to the 
probabilistic projections are quite different. The former 
simulation has higher projected costs, claims for life years 
gained and QALYs gained, yet lower ICERs. In the 
deterministic model lifetime discounted costs range from 
£7,188 for warfarin to £8,983 for apixaban; in the 
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probabilistic model the range is from £5,331 for warfarin to 
£7,228 for apixaban. Corresponding life years gained are 
7.469 to 7.614 and 6.869 to 7.002 for the deterministic as 
opposed to probabilistic model. Projected days gained over 
warfarin are slightly higher for the deterministic simulation. A 
similar pattern is reported for QALYs gained. In the 
deterministic model they are consistently (yet marginally) 
higher ranging from 5.696 to 5.860. Days gained over 
warfarin in the deterministic model range from 22.6 for 
dabigatran 110mg to 59.9 days gained for apixaban. 
Differences within the four NOACs identified, life days and 
QALYs gained are minimal. In the deterministic model life 
days gained over warfarin range from12.24 to 52.20 and for 
QALY days the range is 22.6 to 59.9.  
 
In both the deterministic and probabilistic incremental 
results, dabigatran 110 mg is strictly dominated by dabigatran 
blend (150 mg/110 mg) with apixaban extendedly dominated 
rivaroxaban and dabigatran blend. Apixaban had an ICER 
versus warfarin of £11,008 and £16,852 in the deterministic 
and probabilistic incremental analyses, respectively.  
 
 
Table 2 
 
Lifetime Base-Case Modeled QALY Claims for NOACs: Nice Single Technology Appraisal for Apixaban 
NOAC Costs 
(£) 
Life 
years 
gained 
Life 
years 
gained 
over 
warfarin 
Life 
days 
gained 
over 
warfarin 
QALYs 
gained 
QALYs 
gained 
over 
warfarin 
QALY 
days 
gained 
over 
warfarin 
Incremental 
QALYs 
gained** 
ICER vs. 
warfarin 
(£) 
Deterministic*           
Warfarin 7,188 7.469 - - 5.696 - - - - 
Dabigatran (150/110mg) 8,437 7.537 0.068 24.48 5.788 0.092 33.6 0.091 13,648 
Dabigatran (110 mg) 8,634 7.503 0.034 12.24 5.756 0.060 22.6 -0.032 25,308 
Rivaroxaban 8,778 7.553 0.084 30.24 5.809 0.113 41.2 0.054 14,071 
Apixaban 8,983 7.614 0.145 52.20 5.860 0.164 59.9 0.05 11,008 
Probabilistic*          
Warfarin 5,331 6.869 - - 5.303 - - - - 
Dabigatran (150/110mg) 6,737 6.921 0.052 18.72 5.342 0.039 14.24 0.04 36,4505 
Dabigatran (110 mg) 6,832 6.889 0.030 10.80 5.321 0.018 6.6 -0.02 83,628 
Rivaroxaban 7,070 6.943 0.074 26.60 5.366 0.063 23.0 0.05 27,565 
Apixaban 7,228 7.002 0.133 47.90 5.416 0.113 41.2 0.05 16,852 
Note: in the deterministic simulation mean values are used for each parameter; in the probabilistic simulation distributions are used 
**versus the next least costly technology. Source: Ref 25 
 
Discussion 
All of the studies considered in this review modeled the 
comparative claims for the four NOACs and warfarin in a 
lifetime (or long-term) cost per quality adjusted life year 
(QALY) framework. Presumably, the authors of the various 
studies accepted the cost-utility NICE reference case as the 
appropriate standard. If we accept the scientific method and 
the evidentiary standards of normal science, this is an 
unfortunate choice of evaluation framework as it is 
impossible for the projected claims to be evaluated 17 19 . The 
choice of time horizon precludes testable claims. In this 
context, the claims are immune to failure. None of authors 
recognized this limitation and none attempted to generate 
testable claims or to suggest how the framework of the 
model might be utilized to develop and evaluate claims for 
these competing interventions. None of the authors 
cautioned as to the implications of generating non-testable 
claims for the credibility of the analysis. There was no 
consideration given as to how, if this was the intent of the 
analysis, these lifetime cost-per-QALY claims in respect of 
QALYs gained and incremental-cost-per-QALY estimates 
might be factored into formulary decisions. 
 
Clearly, considerable effort was put into developing these 
modeled claims. Studies ranged from single comparator 
claims contrasting an individual NOAC against warfarin as 
well as those studies that attempted a comparison across 
competing NOACs with warfarin as the baseline comparison. 
Considerable attention was given to justifying the Markov 
structure, the cycle length and the number of health states 
captured in the Markov process. A number of studies 
extended the analysis from a deterministic to a probabilistic 
framework, presenting results for a deterministic base-case 
analysis to a range of probabilistic sensitivity analyses. The 
clinical input event data for both the individual NOACs and 
warfarin were typically referenced back to the pivotal RCTs 
and converted to rates that corresponded to the cycle length. 
Background mortality was based on country-specific life 
tables and mortality attributable to the specific clinical events 
was both included in most models. In all models considerable 
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detail was provided on the drug and event cost assumptions. 
These typically include drug acquisition costs and 
assumptions regarding the frequency and cost of physician 
visits. Given the focus on generating QALY estimates as the 
gold standard endpoint, considerable effort was also directed 
to justifying the utility weights to be attached to the various 
Markov health states. None of the pivotal trials included 
quality of life as a secondary efficacy outcome. Utility weights 
were generated, therefore, from literature reviews. There 
was considerable variation in the scope of the literature 
review. 
 
A key point to note is that, in presenting modeled or 
simulated projections, irrespective of the inherent complexity 
and attractiveness of the model, the evidence presented (the 
claims for comparative advantage) is constructed. From the 
perspective of the agreed standards of normal science, the 
puzzling feature of these attempts to assess (and justify) the 
entrance and formulary acceptance of the NOACs is why they 
are presented in a framework that generates non-testable 
claims? And why, over some 6 or 7 years, have analysts 
persisted in replicating this approach?  13 14 15 It might also be 
reasonable to ask why journal editors have accepted these 
projections at face value? Projections based on the lifetime 
cost-per-QALY standards of the reference case have no 
possibility of ever being evaluated and challenged. It seems 
unreasonable that an editor would accept the projection as 
provisional, subject to the hope that it would be put in an 
evaluable form and the results of a future evaluation 
reported. If this is the case then it may go some way to 
providing an explanation for the backlog of cost-effectiveness 
projections that have been published over the past 20 years 
but never evaluated. 
 
In the case of the NICE reference case it is apparent that 
there is no intention of evaluating the simulated claims 17 60. 
There is no requirement in the reference case for the 
projections to be put in an evaluable form, supported by a 
protocol that details how the projected claims might be 
evaluated and reported back for further appraisal by NICE. 
Rather, the standards support, for chronic diseases, a lifetime 
horizon. This guarantees that the projections have to be 
taken at face value. 
 
Justifying Lifetime Cost-Utility Models 
If the NICE reference case is accepted as the gold standard for 
modeled claims, then we are, in effect, adopting a relativist 
position 61. For the relativist, attempting to assess these 
studies from the perspective of normal science is to miss the 
point. There is no intention to generate claims that have the 
potential to be empirically evaluated. There is no intention to 
subscribe to the standards of normal science. The NICE 
reference case is more appropriately viewed as a construct, 
validated by the ERG process and the final adjudication by the 
NICE advisory committee to support threshold pricing 
decisions. The matching of projected ICERs against national 
notional willingness-to-pay thresholds in a number of the 
studies reviewed here confirms the acceptance of the NICE 
paradigm.  
 
The relativist believes that all perspectives are equally valid. 
In the relativist’s advocacy of the equivalence or symmetry 
principle, health care decisions are to be understood 
sociologically. No one body of evidence is superior to 
another. Results of a simulation are on an equal basis with 
those of a RCT. For the relativist the success of a scientific 
research program, in this case one of non-testable 
projections built on models and simulations, rests not on its 
ability to generate new knowledge but on its ability to 
mobilize the support of the technology assessment 
community. Basing decisions on models and simulations 
underpins the consensus view that evidence is constructed, 
never discovered. Instead of coming to grips with reality 
science is about rhetoric, persuasion and authority.  
Truth is consensus 62. 
 
If we accept the relativist opinion and argue that decisions for 
formulary listing are most appropriately based on non-
testable claims generated by models and simulations then we 
have to address the possibility that simulations can fail. 
Simulations or models are accepted because in the consensus 
view, the view of the authorities in the discipline, the ability 
to capture what they see as the critical or corresponding 
features of the reality of a decision is all that is required. If 
the simulated input conditions and the simulated core 
mechanism correspond to reality, the sufficient condition 
character of the simulation assures us that the output is 
necessarily entailed and predictions must corresponded to 
reality 62. In the evaluation of apixaban described above, 
choice of a probabilistic framework as opposed to the 
manufacturer’s choice of a deterministic model produces 
quite different projections  4. Indeed, if we consider the 
models presented in Table 1 it is reasonable to infer that 
there is considerable latitude in the choice of model to 
support a product specific comparative QALY and cost-
effectiveness claims based on willingness-to-pay thresholds. 
This is illustrated in the Sorensen et al paper which, in the 
case of dabigatran incremental QALY and cost-effectiveness 
claims 42. While Sorensen et al concluded that the various 
models ‘reached generally similar conclusions’ in respect of 
the cost-effectiveness of dabigatran, there were some 
substantive differences in model design and in the inability to 
replicate the claimed QALY results.   
 
It is unlikely ever to be agreement on correspondence, 
sufficiency and necessary entailment in lifetime cost-per-
QALY models. Practitioners can agree that a Markov process 
is appropriate to capture the natural course of a disease, yet 
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disagree on the cycle length, the number of health states and 
transition probabilities that the model accommodates. 
Indeed, it is always possible to reverse engineer any 
simulation to generate competing claims. Apart from a 
probably fruitless debate over competing ‘core’ models, the 
assumptions driving the model and the validity of data that is 
trawled from the literature to populate the model there is no 
basis, apart from an appeal to experimentation that could 
distinguish one modeled or simulated claims from others.  
Rather than capturing the essence of a decision problem, the 
simulation captures the perception of the essence of the 
problem held by the authors of the simulation guided by a 
reference case or similar standards. We are asked to believe 
that it is possible capture the both present clinical reality and 
that reality will continue to unfold and present itself over 
succeeding decades. From the perspective of standards that 
are commonly accepted in evaluation and replication of 
evaluable claims, these models are best characterized as 
pseudoscience; intelligent design as opposed to natural 
selection 63.   
 
Persistence, Adherence and Discontinuation 
Three features of the pivotal trials for the four NOACs should 
be noted. First, the sheer numbers enrolled and the number 
of observations supporting the intention to treat analysis; 
second, the length of the respective trials; and third, the rates 
of discontinuation or persistence. In the case of rivaroxaban, 
14,264 patients underwent randomization in the period 
December 2006 through June 2009; with study termination in 
May 2010 3. A total of 23.7% in the rivaroxaban arm and 
22.2% in the warfarin arm permanently stopped their 
assigned therapy before an end-point event and before the 
study termination date, with 14.3% discontinuing in the first 
12 months. The median duration of treatment exposure was 
20 months.  
 
In the case of dabigatran, 18,113 patients were enrolled and 
randomized between December 2005 and December 2007, 
with final follow-up visits between December 2008 and 
March 2009 2. At year 1, rates of discontinuation were 14.5% 
for dabigatran 110mg, 15.5% for dabigatran 150mg and 
10.2% for warfarin (at 2 years the corresponding figures were 
20.7%, 21.2% and 16.6%). Median duration of follow-up was 
2 years. For apixaban 18,140 patients were enrolled between 
December 2006 and April 2010 1. Discontinuation before the 
end of the study was 25.3% for apixaban (3.6% due to death) 
and 27.5% for warfarin (3.8% due to death). Finally, in the 
case of edoxaban 21,026 patients were enrolled and 
randomized between November 2008 and November 2010. 
Median duration of treatment exposure was 907 days. In the 
warfarin arm 34.4% of patients permanently discontinued 
therapy prematurely and 33.6% for the two edoxaban arms 
(34.3% and 32.8%).  
 
A recent assessment of rates of premature discontinuation in 
long-term NOAC clinical trials also points to a substantial 
proportion of patients discontinuing therapy prematurely 64. 
Across ten long-term trials unscheduled cessation within the 
NOAC arm ranged from 11.3% to 34.4%, with discontinuation 
due to adverse events ranging from 1.7% to 17.2%.  The 
duration of follow-up to assess these premature 
discontinuations ranged from 3 months to just under 3 years. 
These patterns of discontinuation are not, however, out of 
line with those for other vitamin K antagonists with 
randomized clinical trials. Chatterjee et al, from a meta-
analysis of 18 randomized trials, found a risk ratio for 
discontinuation of NOACs versus other vitamin K antagonists 
for all causes in atrial fibrillation 1.01(95% CI 0.87 – 1.17) 65. 
 
In the studies reviewed here, the practice was to apply 
discontinuation and average rates of adherence and 
persistence (where they are applied) generated by the long-
term clinical trials supporting the individual NOACs. Apart 
from differences in the protocols supporting these trials, trial 
based estimates of discontinuation are unlikely to be a 
satisfactory basis for extrapolating modeled claims and 
constructing simulation models. While treatment switching 
and discontinuation of treatment is a feature of virtually all of 
the lifetime models, none of the models factor in observed 
patterns of adherence and persistence over the study time 
horizon. The Dorian et al model, for example, assumes that 
only patients experiencing stroke or MI were assumed to 
discontinue treatment permanently 55 . In a number of the 
models survivors of major bleeding were assumed to stop 
anticoagulation therapy and switch to aspirin. The Wu et al 
study for China made no mention of the need to 
accommodate adherence and persistence within the model, 
apart from mentioning that treatment administered in clinical 
practice might not be effective as one administered in clinical 
trials given lower levels of adherence 36 . The Miguel et al 
model of dabigatran versus warfarin similarly makes no 
mention of adherence of persistence with therapy 48. The two 
Rognoni et al papers which focus on claim from the 
perspective of the Italian health system similarly make no 
mention of adherence or persistence in their simulations 40 58. 
Models to explicitly consider all cause persistence and 
discontinuation are found in two warfarin versus rivaroxaban 
papers: the Morais et al model for Portugal and the Kourlaba 
et al model for Greece 50 53. For the initial 3-month cycle, a 
discontinuation rate from the ROCKET trial of 8.9% was 
assumed for rivaroxaban and 8.0% for warfarin; in 
subsequent cycles it was 4.4% and 4.5% respectively.  
 
A recent study by Yao et al compares adherence patterns for 
warfarin with those for rivaroxaban, dabigatran and apixaban 
and their impact on risk of stroke and major bleeding 66. 
During a median follow up of 1.1 years, only 47.5% of NOAC 
patients were adherent, defined as a medication possession 
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ratio (MPR) of ≥ 80%. Adherence to warfarin was 40.2%.  
Apixaban had the highest unadjusted adherence (61.9%) and 
dabigatran the lowest (38.5%). The rivaroxaban rate was 
58.4%. Applying a multivariate logistic regression, adjusted 
adherence rates were 38.7% for warfarin and 47.5% for all 
NOACs. Higher rates of adherence were found across all 
treatments for those at higher risk. For those with a 
CHAa2DS2-VASc ≥ 4 the warfarin adherence was 53.4% and 
the average for the NOACs 59.8%.  
 
Persistence with NOACs has been reported in three recent 
observational studies. Forslund et al utilizing data from the 
administrative health register of the Stockholm region 
evaluated crude and adjusted persistence from the index OAC 
prescription. In the period April 2011 to December 2014 67. At 
the end of the first year crude overall persistence was 88.2% 
and 82.9% at the end of the second year. Persistence with 
warfarin at the end of the first year was 85.0%, apixaban 
85.9%, dabigatran 74.4% and rivaroxaban 77.4%. In the UK, 
Martinez et al reported on persistence with longitudinal data 
from the Primary Care Clinical Practice Research Datalink 
between January 2011 and May 2014 68. Persistence with 
warfarin at the end of the first year was 63.6$ and 79.2% for 
all NOACs. 
  
In Germany, Beyer-Westendorf et al reported persistence 
from primary care patients at 180 days of 66.0% for 
rivaroxaban, 60.3% for dabigatran and 58.1% for VKA. At 1 
year corresponding persistence estimates were 53.1%, 47.3% 
and 25.45% respectively. An MPR ≥ 0.8 was found for 61.4% 
of rivaroxaban and 49.5% of dabigatran patients 69. 
 
Longer term studies suggest that by 3 years from index 
prescriptions no more than 30% of patients met the standard 
of ≥ 80% days covered. There are limited data for longer 
periods. Experience in Australia, for example, in the period 
November-December 2013 to March 2015 with records from 
the Pharmaceutical Benefits Scheme reported by Simons et al 
found that for index prescriptions in a sample of 1,471 atrial 
fibrillation patients  with a mean age of 76 years on NOACs 
and 74 years on warfarin found that 62% discontinued within 
12 months 70. The corresponding figure for NOACs was 30%. 
Only 9% of those on NOACs failed to pick up the first repeat 
prescription compared to 14% of those on warfarin. 
 
Overall, these estimates suggest that by the end of one year 
after the index prescription persistence with warfarin is in the 
range 60 to 70% with a corresponding NOAC rate of 70 to 
80%. By the end of year 2, persistence is likely to be 15 to 
20% lower. Beyond two years is sheer speculation, although it 
would not be unreasonable, given evidence for persistence in 
other chronic disease states that the overwhelming majority 
of patients have discontinued within 3 to 4 years. Given the 
age at which treatment is usually initiated for atrial 
fibrillation, deaths to patients need to be factored in to 
persistence estimates. In the edoxaban pivotal trial, for 
example, 10-8% of patients died before the end of the trial. 
Under reasons for discontinuation death was given in 3.1% of 
warfarin patients and 2.8% of edoxaban patients. 
 
Adherence patterns add a further dimension. Although not 
captured in any of the pivotal trials, other than reporting time 
in therapeutic range for warfarin, adherence is a potentially 
important offset to claimed therapy gains. While it is often 
difficult in observational studies to distinguish adhere from 
discontinuation, their additive effect on projected model end-
points in therapy could be significant.  
 
If the majority of patients initiated to an OAC have 
discontinued therapy, for event related reasons, non-event 
related reasons and death within 3 to 4 years of their initial 
prescription, then it seems rather odd to focus on creating 
projections for discounted direct medical costs and utilities 
over a lifetime horizon. Instead of modeling switching and 
discontinuation behavior over the lifetime of a treatment 
cohort, a more practical and useful approach would be to 
recognize the likelihood of early discontinuation and generate 
comparative predictions for events and costs for a meaningful 
timeframe that can be captured from existing data sources as 
feedback to formulary committees. 
 
Quality Adjusted Life Years 
While application and acceptance of the reference case 
model is understandable in the case of NICE, it is puzzling as 
to why authors continued to ‘replicate’ cost-per-QALY models 
when the simulated NOAC gains were minimal and the only 
points of reference were other non-evaluable claims 
simulations that adopted lifetime Markov processes. The 
QALY standard for constructing endpoints was never 
questioned. There was no consideration of alternative 
endpoints that might be more clinically appropriate as a basis 
for differentiating the OACs. There is no reason why QALYs 
should be accepted as the outcomes gold standard. The 
argument that QALYs allow us to compare interventions 
across disease states and therapeutic areas loses much of it 
impact when it is pointed out that QALYs are seldom 
recorded in electronic medical records (EMRs) and never in 
administrative claims and other ‘big’ data sets. The effect of 
expressing claims in cost-per-QALY terms may simply be to 
erect one more barrier to evaluating claims. It we accept that 
lifetime cost-per-QALY models (or in these evaluations costs-
per- quality adjusted life day) are the gold standard, then 
there is no chance that such modeling exercises will generate 
anything other than an accumulation of constructed and non-
testable projections. 
In the absence of any commitment to falsification and 
replication of experimental claims, there is no basis for 
validating QALY projections other than through re-evaluating 
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simulation input assumptions, model structure and matching 
projections against those from other simulations. The latter 
comparisons illustrate the sensitivity of constructed cost-
utility claims to individual model structures and assumptions. 
In the case of dabigatran, as noted above, the assessment by 
Sorensen et al undertakes a quantitative comparison 
between a reference model and two US and two UK 
simulations. Assumptions that were compared included the 
lifetime modelling approach, the defined patient population 
and their baseline characteristics, treatment effectiveness, 
projected future risk of stroke and bleeding events, cost and 
utility inputs, drug switching and discontinuation. In the UK 
setting differences in the constructed cost-effectiveness 
results were attributed primarily to the cost and utility model 
inputs (e.g., assumed cost and quality of life following 
intracranial haemorrhage), while in the US setting the 
differences went beyond unit cost and utility values to 
adjustments in the risk for intracranial haemorrhage and 
ischaemic stroke as the modelled cohorts aged and 
accommodation of discontinuation due to non-adherence. 
 
If QALY claims are impossible to evaluate experimentally, 
then there is the option of falling back on clinical endpoints: 
non-fatal ischaemic strokes, fatal strokes, non-fatal 
hemorrhagic strokes and deaths. These endpoints are 
currently accessible from claims data and from electronic 
medical records 71. A recent presentation, for example, to the 
American College of Cardiology in April 2016 reports on a 
comparison of differences between rivaroxaban, dabigatran 
and apixaban in preventing stroke or systemic embolism in 
patients with atrial fibrillation 72. Utilizing data from the 
Optum Labs Data Warehouse in the US the study captured 
data from 160,328 patients who had in initiated therapy 
between October 2010 and February 2015. Three propensity 
score matched cohorts based on 19 clinical variables were 
constructed: rivaroxaban vs dabigatran n = 31,574; apixaban 
vs. dabigatran n=12,084; and apixaban vs. rivaroxaban 
n=13,130. The results of the assessment using Cox 
proportional hazard models for an intention to treat analysis 
found that there was no statistically significant differences in 
any of the pairwise comparisons. The only advantage 
observed was a reduced risk of bleeding and major bleeding 
events with apixaban compared to dabigatran and 
rivaroxaban. Rivaroxaban increased major bleeding.   
 
It is not clear, therefore, what is to be gained from 
quantitative, non-experimental assessments of competing 
constructed cost-utility claims in atrial fibrillation. The fact 
that the cost-utility claims generated by these various 
simulations claims were incapable of ever being evaluated 
suggests that the exercise is probably pointless. Rather than 
focusing on lifetime cost-utility simulations, the construction 
and comparison of imaginary NOAC worlds, reviews of 
simulated models might be more productive if they 
addressed the issue of testable claims for the competing 
OACs and the modeling or simulation frameworks that might 
support such claims. 
   
The fundamental objection to simulations driving decision 
making is that there is no opportunity to generate feedback. 
Health systems that have relied on reference case modeling 
and thresholds to support formulary decisions have no idea, 
in the absence of experimental data, whether those claims 
are right or even if they are wrong. Indeed, as the pipeline for 
new entrants to the atrial fibrillation marketplace is crowded, 
what are the implications for the simulation of new 
compounds, consequent patient switching and the likely 
continuing place on formulary of the NOACs? A simulation 
that took an adherence profile into account might conclude 
that the QALY benefits accrue primarily in the first 3 to 4 
years of therapy and to extend to model a further 10 to 20 
years adds little to overall claims for comparative benefits 
and costs when it is likely that patients who persist on 
therapy will switch to new compounds. 
  
Conclusions 
If the arguments presented here are accepted then, from the 
perspective of experimental evidence supporting formulary 
decisions, the lifetime cost-per-QALY reference case is a 
redundant standard. The reference case supports the 
development of simulation models where the projections are 
immune to failure. The only challenge is from competing 
simulations. Rather than accepting the standards of 
falsification and replication, these standards are put to one 
side. The process of the discovery of new facts is not only put 
to one side, it is irrelevant. 
 
This does not mean that models or simulated claims are 
incapable of generating or suggesting testable hypotheses 
that conform to the standards of normal science. Given the 
evidence for anticipated adherence and persistence patterns, 
attempts to generate claims for the competing merits of the 
NOACs and potential benefits from switching from warfarin 
could focus on the more immediate short term. Rather than 
attempting to develop lifetime models, time horizons of, at 
most, 3 to 4 years should be considered for competing cost-
effectiveness claims. These would capture the baseline risk of 
stroke to capture relative treatment effects, generate specific 
claims for the primary efficacy outcome of reducing stroke 
and other potential adverse events, evaluate claims for 
decreasing efficacy of NOACs with increasing creatinine 
clearance, potentially capturing QALYs and identify key cost 
components. Protocols could be developed by manufacturers 
to detail how the clams would be assessed utilizing 
observational data and the time horizon for reporting (and 
publishing) the results. At the same time, manufacturers 
might suggest alternative intervention strategies to support 
adherence behavior.  If the objective is to reduce the risk of 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                           2016, Vol. 7, No. 3, Article 7                          INNOVATIONS in pharmacy   12 
 
stroke and bleeding, the clinical benefits of adherence 
strategies may far outweigh attempts to demonstrate fairly 
trivial and imaginary QALY benefits between the competing 
NOACs and warfarin. The key point is that claims can be 
evaluated and the outcomes reported back to formulary 
committees in a timely manner.  
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